Login Register Cart 0
Generic placeholder image

Current Pharmaceutical Design

Editor-in-Chief

ISSN (Print): 1381-6128
ISSN (Online): 1873-4286

Back
Journal Home About Journal Editorial Board Journal Insight Current Issue Volumes/Issues
Subscribe
Review Article

Folic Acid Conjugated Nanocarriers for Efficient Targetability and Promising Anticancer Efficacy for Treatment of Breast Cancer: A Review of Recent Updates

Author(s): Hira Choudhury, Manisha Pandey*, Lee Pei Wen, Ling Kah Cien, Ho Xin, Alvina Ng Jia Yee, Ng Joo Lee, Bapi Gorain, Mohd Cairul Iqbal Mohd Amin and Mallikarjuna Rao Pichika

Volume 26, Issue 42, 2020

Page: [5365 - 5379] Pages: 15

DOI: 10.2174/1381612826666200721000958

Price: $65

Abstract

Breast cancer (BC) is the commonest cause of cancer deaths among Women. It is known to be caused due to mutations in certain receptors, viz. estrogens or progesterones. The most frequently used conventional treatment strategies against BC include chemotherapy, radiation therapy, and partial or entire mastectomy, however, these strategies are often associated with multiple adverse effects, thus reducing patient compliance. Advancement of nanotechnology in the medical application has been made to enhance the therapeutic effectiveness with a significant reduction in the unintended side-effects associated with incorporated anticancer drugs against cancer. The surface engineering technology of the nanocarriers is more pronounced in delivering the therapeutics specifically to target cells. Consequently, folic acid, a small molecular ligand for the folate receptor overexpressed cells, has shown immense response in treating BC cells. Folic acid conjugated nanocarriers have shown remarkable efficiency in targeting overexpressed folate receptors on the surface of BC cells. Binding of these target-specific folate-conjugated nanocarriers substantially improves the internalization of chemotherapeutics in BC cells, without much exposing the other parts of the body. Simultaneously, these folate-- conjugated nanocarriers provide imaging for regular monitoring of targeted drug delivery systems and their responses to an anticancer therapy. Therefore, this review demonstrates the potential of folate-conjugated nanotherapeutics for the treatment and theranostic approaches against BC along with the significant challenges to anticancer therapy, and the prospective insights into the clinical importance and effectiveness of folate conjugate nanocarriers.

Keywords: Folic acid, folic acid conjugation, breast cancer, nanotechnology, targeted drug delivery, theranostic approach, chemotherapies.

« Previous Next »
[1]
Zbären P, Stauffer E. Pleomorphic adenoma of the parotid gland: histopathologic analysis of the capsular characteristics of 218 tumors. Head Neck 2007; 29(8): 751-7.
[http://dx.doi.org/10.1002/hed.20569] [PMID: 17252593]
[2]
Latest world cancer statistics 2013.
[3]
Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68(6): 394-424.
[http://dx.doi.org/10.3322/caac.21492] [PMID: 30207593]
[4]
Miah S, Bagu E, Goel R, et al. Estrogen receptor signaling regulates the expression of the breast tumor kinase in breast cancer cells. BMC Cancer 2019; 19(1): 78.
[http://dx.doi.org/10.1186/s12885-018-5186-8] [PMID: 30651078]
[5]
Kuchenbaecker KB, Hopper JL, Barnes DR, et al. BRCA1 and BRCA2 Cohort Consortium. Risks of breast, ovarian, and contralateral breast cancer for BRCA1 and BRCA2 mutation carriers. JAMA 2017; 317(23): 2402-16.
[http://dx.doi.org/10.1001/jama.2017.7112] [PMID: 28632866]
[6]
Liu FC, Lin HT, Kuo CF, See LC, Chiou MJ, Yu HP. Epidemiology and survival outcome of breast cancer in a nationwide study. Oncotarget 2017; 8(10): 16939-50.
[http://dx.doi.org/10.18632/oncotarget.15207] [PMID: 28199975]
[7]
World cancer research fund international, breast cancer statistics
[8]
Mullooly M, Nyante SJ, Pfeiffer RM, et al. Involution of breast lobules, mammographic breast density and prognosis among tamoxifen-treated estrogen receptor-positive breast cancer patients. J Clin Med 2019; 8(11): 1868.
[http://dx.doi.org/10.3390/jcm8111868] [PMID: 31689948]
[9]
Lorger M, Felding-Habermann B. Capturing changes in the brain microenvironment during initial steps of breast cancer brain metastasis. Am J Pathol 2010; 176(6): 2958-71.
[http://dx.doi.org/10.2353/ajpath.2010.090838] [PMID: 20382702]
[10]
Hauerslev KR, Madsen AH, Overgaard J, Damsgaard TE, Christiansen P. Long-term follow-up on shoulder and arm morbidity in patients treated for early breast cancer. Acta Oncol 2020; 59(7): 851-8.
[http://dx.doi.org/10.1080/0284186X.2020.1745269] [PMID: 32285717]
[11]
Bowen ME, Mone MC, Buys SS, Sheng X, Nelson EW. Surgical outcomes for mastectomy patients receiving neoadjuvant chemotherapy. Ann Surg 2017; 265(3): 448-56.
[http://dx.doi.org/10.1097/SLA.0000000000001804] [PMID: 27280515]
[12]
Gorain B, Choudhury H, Pandey M, Kesharwani P. Paclitaxel loaded vitamin E-TPGS nanoparticles for cancer therapy. Mater Sci Eng C 2018; 91: 868-80.
[http://dx.doi.org/10.1016/j.msec.2018.05.054] [PMID: 30033322]
[13]
Choudhury H, Gorain B, Pandey M, et al. Recent advances in TPGS-based nanoparticles of docetaxel for improved chemotherapy. Int J Pharm 2017; 529(1-2): 506-22.
[http://dx.doi.org/10.1016/j.ijpharm.2017.07.018] [PMID: 28711640]
[14]
Bergh J, Jönsson P-E, Glimelius B, Nygren P. SBU-group. Swedish Council of Technology Assessment in Health Care. A systematic overview of chemotherapy effects in breast cancer. Acta Oncol 2001; 40(2-3): 253-81.
[http://dx.doi.org/10.1080/02841860151116349] [PMID: 11441936]
[15]
A’Hern RP, Ebbs SR, Baum MB. Does chemotherapy improve survival in advanced breast cancer? A statistical overview. Br J Cancer 1988; 57(6): 615-8.
[http://dx.doi.org/10.1038/bjc.1988.140] [PMID: 3044434]
[16]
Senapati S, Mahanta AK, Kumar S, Maiti P. Controlled drug delivery vehicles for cancer treatment and their performance. Signal Transduct Target Ther 2018; 3: 7.
[http://dx.doi.org/10.1038/s41392-017-0004-3] [PMID: 29560283]
[17]
Rapoport N, Gao Z, Kennedy A. Multifunctional nanoparticles for combining ultrasonic tumor imaging and targeted chemotherapy. J Natl Cancer Inst 2007; 99(14): 1095-106.
[http://dx.doi.org/10.1093/jnci/djm043] [PMID: 17623798]
[18]
Banu H, Sethi DK, Edgar A, et al. Doxorubicin loaded polymeric gold nanoparticles targeted to human folate receptor upon laser photothermal therapy potentiates chemotherapy in breast cancer cell lines. J Photochem Photobiol B 2015; 149: 116-28.
[http://dx.doi.org/10.1016/j.jphotobiol.2015.05.008] [PMID: 26057021]
[19]
Pandey M, Choudhury H, Yeun OC, et al. Perspectives of nanoemulsion strategies in the improvement of oral, parenteral and transdermal chemotherapy. Curr Pharm Biotechnol 2018; 19(4): 276-92.
[http://dx.doi.org/10.2174/1389201019666180605125234] [PMID: 29874994]
[20]
Salvioni L, Rizzuto MA, Bertolini JA, Pandolfi L, Colombo M, Prosperi D. Thirty years of cancer nanomedicine: Success, frustration, and hope. Cancers (Basel) 2019; 11(12): E1855.
[http://dx.doi.org/10.3390/cancers11121855] [PMID: 31769416]
[21]
Cagel M, Tesan FC, Bernabeu E, et al. Polymeric mixed micelles as nanomedicines: Achievements and perspectives. Eur J Pharm Biopharm 2017; 113: 211-28.
[http://dx.doi.org/10.1016/j.ejpb.2016.12.019] [PMID: 28087380]
[22]
Choudhury H, Gorain B, Tekade RK, Pandey M, Karmakar S, Pal TK. Safety against nephrotoxicity in paclitaxel treatment: Oral nanocarrier as an effective tool in preclinical evaluation with marked in vivo antitumor activity. Regul Toxicol Pharmacol 2017; 91: 179-89.
[http://dx.doi.org/10.1016/j.yrtph.2017.10.023] [PMID: 29080846]
[23]
Kumbhar SA, Kokare CR, Shrivastava B, Gorain B, Choudhury H. Preparation, characterization, and optimization of asenapine maleate mucoadhesive nanoemulsion using Box-Behnken design: In vitro and in vivo studies for brain targeting. Int J Pharm 2020; 586: 119499.
[http://dx.doi.org/10.1016/j.ijpharm.2020.119499] [PMID: 32505580]
[24]
Chatterjee B, Gorain B, Mohananaidu K, Sengupta P, Mandal UK, Choudhury H. Targeted drug delivery to the brain via intranasal nanoemulsion: Available proof of concept and existing challenges. Int J Pharm 2019; 565: 258-68.
[http://dx.doi.org/10.1016/j.ijpharm.2019.05.032] [PMID: 31095983]
[25]
Chall S, Mati SS, Gorain B, Rakshit S, Bhattacharya SC. Toxicological assessment of PEG functionalized f-block rare earth phosphate nanorods. Toxicol Res (Camb) 2015; 4
[http://dx.doi.org/10.1039/C5TX00049A]
[26]
Lombardo D, Kiselev MA, Caccamo MT. Smart nanoparticles for drug delivery application: Development of versatile nanocarrier platforms in biotechnology and nanomedicine. J Nanomater 2019.
[27]
Patra JK, Das G, Fraceto LF, et al. Nano based drug delivery systems: Recent developments and future prospects. J Nanobiotechnology 2018; 16(1): 71.
[http://dx.doi.org/10.1186/s12951-018-0392-8] [PMID: 30231877]
[28]
Hoshyar N, Gray S, Han H, Bao G. The effect of nanoparticle size on in vivo pharmacokinetics and cellular interaction. Nanomedicine (Lond) 2016; 11(6): 673-92.
[http://dx.doi.org/10.2217/nnm.16.5] [PMID: 27003448]
[29]
Kang H, Rho S, Stiles WR, et al. Size-dependent EPR effect of polymeric nanoparticles on tumor targeting. Adv Healthc Mater 2020; 9(1): e1901223.
[http://dx.doi.org/10.1002/adhm.201901223] [PMID: 31794153]
[30]
Kumar A, Lale SV, Aji Alex MR, Choudhary V, Koul V. Folic acid and trastuzumab conjugated redox responsive random multiblock copolymeric nanocarriers for breast cancer therapy: In-vitro and in-vivo studies. Colloids Surf B Biointerfaces 2017; 149: 369-78.
[http://dx.doi.org/10.1016/j.colsurfb.2016.10.044] [PMID: 27846450]
[31]
Jin K-T, Lu Z-B, Chen J-Y, et al. Recent trends in nanocarrier-based targeted chemotherapy: Selective delivery of anticancer drugs for effective lung, colon, cervical, and breast cancer treatment. J Nanomater 2020; 2020: 14.
[http://dx.doi.org/10.1155/2020/9184284]
[32]
Duan D, Wang A, Ni L, et al. Trastuzumab- and Fab' fragment-modified curcumin PEG-PLGA nanoparticles: preparation and evaluation in vitro and in vivo. Int J Nanomedicine 2018; 13: 1831-40.
[http://dx.doi.org/10.2147/IJN.S153795] [PMID: 29606874]
[33]
Davis ME, Chen ZG, Shin DM. Nanoparticle therapeutics: an emerging treatment modality for cancer. Nat Rev Drug Discov 2008; 7(9): 771-82.
[http://dx.doi.org/10.1038/nrd2614] [PMID: 18758474]
[34]
Derakhshandeh K, Azandaryani AH. Active-targeted nanotherapy as smart cancer treatment.Smart Drug DelivSyst InTech. 2016.
[http://dx.doi.org/10.5772/61791]
[35]
Kesharwani P, Choudhury H, Meher JG, Pandey M, Gorain B. Dendrimer-entrapped gold nanoparticles as promising nanocarriers for anticancer therapeutics and imaging. Prog Mater Sci 2019; 103: 484-508.
[http://dx.doi.org/10.1016/j.pmatsci.2019.03.003]
[36]
Choudhury H, Maheshwari R, Pandey M, Tekade M, Gorain B, Tekade RK. Advanced nanoscale carrier-based approaches to overcome biopharmaceutical issues associated with anticancer drug ‘Etoposide’. Mater Sci Eng C 2020; 106: 110275.
[http://dx.doi.org/10.1016/j.msec.2019.110275] [PMID: 31753398]
[37]
Yoo J, Park C, Yi G, Lee D, Koo H. Active targeting strategies using biological ligands for nanoparticle drug delivery systems. Cancers (Basel) 2019; 11(5): 640.
[http://dx.doi.org/10.3390/cancers11050640] [PMID: 31072061]
[38]
Kobayashi K, Wei J, Iida R, Ijiro K, Niikura K. Surface engineering of nanoparticles for therapeutic applications. Polym J 2014; 46: 460-8.
[http://dx.doi.org/10.1038/pj.2014.40]
[39]
Leserman LD, Barbet J, Kourilsky F, Weinstein JN. Targeting to cells of fluorescent liposomes covalently coupled with monoclonal antibody or protein A. Nature 1980; 288(5791): 602-4.
[http://dx.doi.org/10.1038/288602a0] [PMID: 7442804]
[40]
Attia MF, Anton N, Wallyn J, Omran Z, Vandamme TF. An overview of active and passive targeting strategies to improve the nanocarriers efficiency to tumour sites. J Pharm Pharmacol 2019; 71(8): 1185-98.
[http://dx.doi.org/10.1111/jphp.13098] [PMID: 31049986]
[41]
Howell SJ, Johnston SRD, Howell A. The use of selective estrogen receptor modulators and selective estrogen receptor down-regulators in breast cancer. Best Pract Res Clin Endocrinol Metab 2004; 18(1): 47-66.
[http://dx.doi.org/10.1016/j.beem.2003.08.002] [PMID: 14687597]
[42]
Schneider R, Barakat A, Pippen J, Osborne C. Aromatase inhibitors in the treatment of breast cancer in post-menopausal female patients: an update. Breast Cancer (Dove Med Press) 2011; 3: 113-25.
[http://dx.doi.org/10.2147/BCTT.S22905] [PMID: 24367181]
[43]
Pernas S, Tolaney SM. HER2-positive breast cancer: new therapeutic frontiers and overcoming resistance. Ther Adv Med Oncol 2019; 11: 1758835919833519.
[http://dx.doi.org/10.1177/1758835919833519] [PMID: 30911337]
[44]
Maximiano S, Magalhães P, Guerreiro MP, Morgado M. Trastuzumab in the treatment of breast cancer. BioDrugs 2016; 30(2): 75-86.
[http://dx.doi.org/10.1007/s40259-016-0162-9] [PMID: 26892619]
[45]
Mitri Z, Constantine T, O’Regan R. The HER2 receptor in breast cancer: pathophysiology, clinical use, and new advances in therapy. Chemother Res Pract 2012; 2012: 743193.
[46]
Tanei T, Choi DS, Rodriguez AA, et al. Antitumor activity of Cetuximab in combination with Ixabepilone on triple negative breast cancer stem cells. Breast Cancer Res 2016; 18(1): 6.
[http://dx.doi.org/10.1186/s13058-015-0662-4] [PMID: 26757880]
[47]
Tiainen L, Tanner M, Lahdenperä O, et al. Bevacizumab combined with docetaxel or paclitaxel as first-line treatment of HER2-negative metastatic breast cancer. Anticancer Res 2016; 36(12): 6431-8.
[http://dx.doi.org/10.21873/anticanres.11241] [PMID: 27919965]
[48]
Toporkiewicz M, Meissner J, Matusewicz L, Czogalla A, Sikorski AF. Toward a magic or imaginary bullet? Ligands for drug targeting to cancer cells: Principles, hopes, and challenges. Int J Nanomedicine 2015; 10: 1399-414.
[http://dx.doi.org/10.2147/IJN.S74514] [PMID: 25733832]
[49]
Chen C, Ke J, Zhou XE, et al. Structural basis for molecular recognition of folic acid by folate receptors. Nature 2013; 500(7463): 486-9.
[http://dx.doi.org/10.1038/nature12327] [PMID: 23851396]
[50]
Assaraf YG, Leamon CP, Reddy JA. The folate receptor as a rational therapeutic target for personalized cancer treatment. Drug Resist Updat 2014; 17(4-6): 89-95.
[http://dx.doi.org/10.1016/j.drup.2014.10.002] [PMID: 25457975]
[51]
Ramzy L, Nasr M, Metwally AA, Awad GAS. Cancer nanotheranostics: A review of the role of conjugated ligands for overexpressed receptors. Eur J Pharm Sci 2017; 104: 273-92.
[http://dx.doi.org/10.1016/j.ejps.2017.04.005] [PMID: 28412485]
[52]
Norton N, Youssef B, Hillman DW, et al. Folate receptor alpha expression associates with improved disease-free survival in triple negative breast cancer patients. NPJ Breast Cancer 2020; 6: 4.
[http://dx.doi.org/10.1038/s41523-020-0147-1] [PMID: 32047850]
[53]
Ledermann JA, Canevari S, Thigpen T. Targeting the folate receptor: diagnostic and therapeutic approaches to personalize cancer treatments. Ann Oncol 2015; 26(10): 2034-43.
[http://dx.doi.org/10.1093/annonc/mdv250] [PMID: 26063635]
[54]
Cheung A, Bax HJ, Josephs DH, et al. Targeting folate receptor alpha for cancer treatment. Oncotarget 2016; 7(32): 52553-74.
[http://dx.doi.org/10.18632/oncotarget.9651] [PMID: 27248175]
[55]
Pieroth R, Paver S, Day S, Lammersfeld C. Folate and its impact on cancer risk. Curr Nutr Rep 2018; 7(3): 70-84.
[http://dx.doi.org/10.1007/s13668-018-0237-y] [PMID: 30099693]
[56]
Kelemen LE. The role of folate receptor α in cancer development, progression and treatment: cause, consequence or innocent bystander? Int J Cancer 2006; 119(2): 243-50.
[http://dx.doi.org/10.1002/ijc.21712] [PMID: 16453285]
[57]
Xu L, Bai Q, Zhang X, Yang H. Folate-mediated chemotherapy and diagnostics: An updated review and outlook. J Control Release 2017; 252: 73-82.
[http://dx.doi.org/10.1016/j.jconrel.2017.02.023] [PMID: 28235591]
[58]
Bakrania AK, Variya BC, Patel SS. Novel targets for paclitaxel nano formulations: Hopes and hypes in triple negative breast cancer. Pharmacol Res 2016; 111: 577-91.
[http://dx.doi.org/10.1016/j.phrs.2016.07.023] [PMID: 27461138]
[59]
Ritter TE, Fajardo O, Matsue H, Anderson RGW, Lacey SW. Folate receptors targeted to clathrin-coated pits cannot regulate vitamin uptake. Proc Natl Acad Sci USA 1995; 92(9): 3824-8.
[http://dx.doi.org/10.1073/pnas.92.9.3824] [PMID: 7731991]
[60]
Sabharanjak S, Mayor S. Folate receptor endocytosis and trafficking. Adv Drug Deliv Rev 2004; 56(8): 1099-109.
[http://dx.doi.org/10.1016/j.addr.2004.01.010] [PMID: 15094209]
[61]
Fernández M, Javaid F, Chudasama V. Advances in targeting the folate receptor in the treatment/imaging of cancers. Chem Sci (Camb) 2017; 9(4): 790-810.
[http://dx.doi.org/10.1039/C7SC04004K] [PMID: 29675145]
[62]
Vinothini K, Rajendran NK, Ramu A, Elumalai N, Rajan M. Folate receptor targeted delivery of paclitaxel to breast cancer cells via folic acid conjugated graphene oxide grafted methyl acrylate nanocarrier. Biomed Pharmacother 2019; 110: 906-17.
[http://dx.doi.org/10.1016/j.biopha.2018.12.008] [PMID: 30572195]
[63]
Erdoğar N, Esendağlı G, Nielsen TT, Şen M, Öner L, Bilensoy E. Design and optimization of novel paclitaxel-loaded folate-conjugated amphiphilic cyclodextrin nanoparticles. Int J Pharm 2016; 509(1-2): 375-90.
[http://dx.doi.org/10.1016/j.ijpharm.2016.05.040] [PMID: 27282534]
[64]
Song C. Folate-modified lipid – polymer hybrid nanoparticles for targeted paclitaxel delivery. 2015; 2101-14.
[65]
Zhong P, Chen X, Guo R, et al. Folic Acid-Modified nanoerythrocyte for codelivery of paclitaxel and tariquidar to overcome breast cancer multidrug resistance. Mol Pharm 2020; 17(4): 1114-26.
[http://dx.doi.org/10.1021/acs.molpharmaceut.9b01148] [PMID: 32176509]
[66]
Ağardan NBM, Torchilin VP. Engineering of stimuli-sensitive nanopreparations to overcome physiological barriers and cancer multidrug resistance.Eng Nanobiomaterials. Elsevier 2016; pp. 1-28.
[http://dx.doi.org/10.1016/B978-0-323-41532-3.00001-4]
[67]
Lale SV, R G A, Aravind A, Kumar DS, Koul V. AS1411 aptamer and folic acid functionalized pH-responsive ATRP fabricated pPEGMA-PCL-pPEGMA polymeric nanoparticles for targeted drug delivery in cancer therapy. Biomacromolecules 2014; 15(5): 1737-52.
[http://dx.doi.org/10.1021/bm5001263] [PMID: 24689987]
[68]
Pang Z, Zhou J, Sun C. Ditelluride-Bridged PEG-PCL Copolymer as folic acid-targeted and redox-Responsive nanoparticles for enhanced cancer therapy. Front Chem 2020; 8: 156-61.
[http://dx.doi.org/10.3389/fchem.2020.00156] [PMID: 32181244]
[69]
Kumar P, Tambe P, Paknikar KM, Gajbhiye V. Folate/N-acetyl glucosamine conjugated mesoporous silica nanoparticles for targeting breast cancer cells: A comparative study. Colloids Surf B Biointerfaces 2017; 156: 203-12.
[http://dx.doi.org/10.1016/j.colsurfb.2017.05.032] [PMID: 28531877]
[70]
Jang C, Lee JH, Sahu A, Tae G. The synergistic effect of folate and RGD dual ligand of nanographene oxide on tumor targeting and photothermal therapy in vivo. Nanoscale 2015; 7(44): 18584-94.
[http://dx.doi.org/10.1039/C5NR05067G] [PMID: 26489965]
[71]
Chen L, Zhou L, Wang C, et al. Tumor-Targeted Drug and CpG delivery System for phototherapy and docetaxel-enhanced immunotherapy with polarization toward M1-type macrophages on triple negative breast cancers. Adv Mater 2019; 31(52): e1904997.
[http://dx.doi.org/10.1002/adma.201904997] [PMID: 31721331]
[72]
Tavassolian F, Kamalinia G, Rouhani H, et al. Targeted poly (L-γ-glutamyl glutamine) nanoparticles of docetaxel against folate over-expressed breast cancer cells. Int J Pharm 2014; 467(1-2): 123-38.
[http://dx.doi.org/10.1016/j.ijpharm.2014.03.033] [PMID: 24680951]
[73]
Nateghian N, Goodarzi N, Amini M, Atyabi F, Khorramizadeh MR, Dinarvand R. Biotin/Folate-decorated human serum albumin nanoparticles of docetaxel: Comparison of chemically conjugated nanostructures and physically loaded nanoparticles for targeting of breast cancer. Chem Biol Drug Des 2016; 87(1): 69-82.
[http://dx.doi.org/10.1111/cbdd.12624] [PMID: 26216713]
[74]
Abazari R, Ataei F, Morsali A, Slawin AMZ, L Carpenter-Warren C. A Luminescent amine-functionalized metal-organic framework conjugated with folic acid as a cargeted biocompatible pH-responsive nanocarrier for apoptosis induction in breast cancer cells. ACS Appl Mater Interfaces 2019; 11(49): 45442-54.
[http://dx.doi.org/10.1021/acsami.9b16473] [PMID: 31718155]
[75]
El-Hammadi MM, Delgado ÁV, Melguizo C, Prados JC, Arias JL. Folic acid-decorated and PEGylated PLGA nanoparticles for improving the antitumour activity of 5-fluorouracil. Int J Pharm 2017; 516(1-2): 61-70.
[http://dx.doi.org/10.1016/j.ijpharm.2016.11.012] [PMID: 27825867]
[76]
Gunduz U, Keskin T, Tansık G, et al. Idarubicin-loaded folic acid conjugated magnetic nanoparticles as a targetable drug delivery system for breast cancer. Biomed Pharmacother 2014; 68(6): 729-36.
[http://dx.doi.org/10.1016/j.biopha.2014.08.013] [PMID: 25194441]
[77]
Chen J, Li S, Shen Q. Folic acid and cell-penetrating peptide conjugated PLGA-PEG bifunctional nanoparticles for vincristine sulfate delivery. Eur J Pharm Sci 2012; 47(2): 430-43.
[http://dx.doi.org/10.1016/j.ejps.2012.07.002] [PMID: 22796217]
[78]
Tagde P, Kulkarni G, Mishra DK, Kesharwani P. Recent advances in folic acid engineered nanocarriers for treatment of breast cancer. J Drug Deliv Sci Technol 2020; 56: 101613.
[http://dx.doi.org/10.1016/j.jddst.2020.101613]
[79]
Wang Y, Dou L, He H, Zhang Y, Shen Q. Multifunctional nanoparticles as nanocarrier for vincristine sulfate delivery to overcome tumor multidrug resistance. Mol Pharm 2014; 11(3): 885-94.
[http://dx.doi.org/10.1021/mp400547u] [PMID: 24483832]
[80]
Esfandiarpour-Boroujeni S, Bagheri-Khoulenjani S, Mirzadeh H, Amanpour S. Fabrication and study of curcumin loaded nanoparticles based on folate-chitosan for breast cancer therapy application. Carbohydr Polym 2017; 168: 14-21.
[http://dx.doi.org/10.1016/j.carbpol.2017.03.031] [PMID: 28457434]
[81]
Mollarazi E, Jalilian AR, Johari-Daha F, Atyabi F. Development of (153) Sm-folate-polyethyleneimine-conjugated chitosan nanoparticles for targeted therapy. J Labelled Comp Radiopharm 2015; 58(8): 327-35.
[http://dx.doi.org/10.1002/jlcr.3305] [PMID: 26036233]
[82]
Liu M, Wang B, Guo C, Hou X, Cheng Z, Chen D. Novel multifunctional triple folic acid, biotin and CD44 targeting pH-sensitive nano-actiniaes for breast cancer combinational therapy. Drug Deliv 2019; 26(1): 1002-16.
[http://dx.doi.org/10.1080/10717544.2019.1669734] [PMID: 31571501]
[83]
Muthu MS, Leong DT, Mei L, Feng S-S. Nanotheranostics - application and further development of nanomedicine strategies for advanced theranostics. Theranostics 2014; 4(6): 660-77.
[http://dx.doi.org/10.7150/thno.8698] [PMID: 24723986]
[84]
Nejadshafiee V, Naeimi H, Goliaei B, et al. Magnetic bio-metal-organic framework nanocomposites decorated with folic acid conjugated chitosan as a promising biocompatible targeted theranostic system for cancer treatment. Mater Sci Eng C 2019; 99: 805-15.
[http://dx.doi.org/10.1016/j.msec.2019.02.017] [PMID: 30889755]
[85]
Soleymani M, Khalighfard S, Khodayari S, et al. Effects of multiple injections on the efficacy and cytotoxicity of folate-targeted magnetite nanoparticles as theranostic agents for MRI detection and magnetic hyperthermia therapy of tumor cells. Sci Rep 2020; 10(1): 1695.
[http://dx.doi.org/10.1038/s41598-020-58605-3] [PMID: 32015364]
[86]
Heidari Majd M, Asgari D, Barar J, et al. Tamoxifen loaded folic acid armed PEGylated magnetic nanoparticles for targeted imaging and therapy of cancer. Colloids Surf B Biointerfaces 2013; 106: 117-25.
[http://dx.doi.org/10.1016/j.colsurfb.2013.01.051] [PMID: 23434700]
[87]
Heidari Majd M, Barar J, Asgari D, et al. Targeted fluoromagnetic nanoparticles for imaging of breast cancer mcf-7 cells. Adv Pharm Bull 2013; 3(1): 189-95.
[http://dx.doi.org/10.5681/apb.2013.031] [PMID: 24312834]
[88]
Barar J, Kafil V, Majd MH, et al. Multifunctional mitoxantrone-conjugated magnetic nanosystem for targeted therapy of folate receptor-overexpressing malignant cells. J Nanobiotechnology 2015; 13: 26.
[http://dx.doi.org/10.1186/s12951-015-0083-7] [PMID: 25880772]
[89]
Huang Y, Mao K, Zhang B, Zhao Y. Superparamagnetic iron oxide nanoparticles conjugated with folic acid for dual target-specific drug delivery and MRI in cancer theranostics. Mater Sci Eng C 2017; 70(Pt 1): 763-71.
[http://dx.doi.org/10.1016/j.msec.2016.09.052] [PMID: 27770953]
[90]
Pan C, Liu Y, Zhou M, et al. Theranostic pH-sensitive nanoparticles for highly efficient targeted delivery of doxorubicin for breast tumor treatment. Int J Nanomedicine 2018; 13: 1119-37.
[http://dx.doi.org/10.2147/IJN.S147464] [PMID: 29520140]
[91]
Zhou F, Feng B, Yu H, et al. Cisplatin prodrug-conjugated gold nanocluster for fluorescence imaging and targeted therapy of the breast cancer. Theranostics 2016; 6(5): 679-87.
[http://dx.doi.org/10.7150/thno.14556] [PMID: 27022415]
[92]
Diaz-Diestra D, Thapa B, Badillo-Diaz D, Beltran-Huarac J, Morell G, Weiner BR. Graphene oxide/ZnS:Mn nanocomposite functionalized with folic acid as a nontoxic and effective theranostic platform for breast cancer treatment. Nanomaterials (Basel) 2018; 8(7): E484.
[http://dx.doi.org/10.3390/nano8070484] [PMID: 29966355]
[93]
Bwatanglang IB, Mohammad F, Yusof NA, et al. Folic acid targeted Mn:ZnS quantum dots for theranostic applications of cancer cell imaging and therapy. Int J Nanomedicine 2016; 11: 413-28.
[http://dx.doi.org/10.2147/IJN.S90198] [PMID: 26858524]
[94]
Alibolandi M, Abnous K, Sadeghi F, Hosseinkhani H, Ramezani M, Hadizadeh F. Folate receptor-targeted multimodal polymersomes for delivery of quantum dots and doxorubicin to breast adenocarcinoma: In vitro and in vivo evaluation. Int J Pharm 2016; 500(1-2): 162-78.
[http://dx.doi.org/10.1016/j.ijpharm.2016.01.040] [PMID: 26802496]

Rights & Permissions Print Cite
Article Metrics
16
1
© 2024 Bentham Science Publishers | Privacy Policy